Table 2 Summary of results from validation studies (level 1B) and the WSG PlanB study (level 1A)
Standard RS cut-offs | |||
|---|---|---|---|
RS <18 | RS 18–30 | RS ≥31 | |
SWOG S8814 (N+; N = 367) | |||
N (%) | 146 (40%) | 103 (28%) | 118 (32%) |
% CT/% no CT | 62%/38% | 55%/45% | 60%/40% |
10-y DFS; HR (95% CI) for CT + HT vs. HT | 1.02 (0.54, 1.93) | 0.72 (0.39, 1.31) | 0.59 (0.35, 1.01) |
p-value | 0.97 | 0.48 | 0.03 |
transATAC (N+; N = 306) | |||
N (%) | 160 (52%) | 94 (31%) | 52 (17%) |
% CT/% no CT | 0%/100% | 0%/100% | 0%/100% |
9-y DR (95% CI) | 17% (12%, 24%) | 28% (20%, 39%) | 49% (35%, 64%) |
p-value | <0.001 (RS results associated with risk of DR) | ||
Non-standard RS cut-offs | |||
RS <12 | RS 12–25 | RS >25 | |
PlanB (1–3N+; N = 905) | |||
N (%) | 170 (19%)a | 567 (63%) | 168 (19%) |
% CT/% no CT | 0%/100%a | 100%/0% | 100%/0% |
5-y DFS (95% CI) | 94.4%a (89.5%, 99.3%) | 94.3% (91.9%, 96.7%) | 83.6% (77.1%, 90.1%) |
p-value | <0.001 | ||
5-y DDFS | 97.9% | 96.0% | 86.0% |
p-value | <0.001 for RS >25 vs. RS <12 or RS 12–25 | ||
